International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting—From Noncirrhotic to Decompensated Disease and After Liver Transplantation

• Published in: Transplantation Vol. 103; no. 4; pp. 733 - 746
• Main Authors: Charlton, Michael R, Gane, Edward J, Shukla, Aakash, Dashtseren, Bekhbold, Duger, Davaadorj, Muljono, David H, Payawal, Diana A, Jargalsaikhan, Ganbolor, Purnomo, Hery D, Cua, Ian H, Hasan, Irsan, Sollano, Jose, Win, Khin Maung, Lesmana, Laurentius A, Salih, Mohammad, Thi Thu Thuy, Pham, Shankar, Ravi, Saraswat, Vivek A
• Format: Journal Article
• Language: English
• Published: United States Copyright Wolters Kluwer Health, Inc. All rights reserved 01-04-2019
• ISSN: 0041-1337; 1534-6080
• DOI: 10.1097/TP.0000000000002453

BACKGROUND.The population of Asia exceeds 4.4 billion people. Chronic hepatitis C virus (HCV) infection in Asia is characterized by specific distribution of genotypes, lack of access to specific therapeutic agents, relatively high cost of treatment, and lack of experienced healthcare providers. Clear consensus on the diagnosis, management, and monitoring of HCV infection specific to the Asian region is a major unmet need. The consensus guidelines documents that have been published to date by major medical societies presume access to an array of direct acting antiviral agents and diagnostic tests that are not broadly applicable to resource limited settings, including Asia.
METHODS.To address the lack of an Asia-specific set of HCV treatment guidelines, we assembled a panel of 15 HCV experts in the field of hepatology from India, Indonesia, Myanmar, Vietnam, Pakistan, Philippines, and Mongolia convened in April 2017 to review the updated literature and provide recommendations on the diagnosis and management of chronic HCV infection that reflects local conditions.
RESULTS.An evidence-based comprehensive compilation of the literature supported by the graded recommendations from the expert panel for the optimization of the diagnosis, pretreatment, on treatment, and posttreatment assessments, and management of chronic HCV infection has been presented in this article.
CONCLUSIONS.With the evolving treatment landscape and addition of several new direct-acting antiviral agents and combination regimens into the therapeutic armamentarium, the current article may serve as a guide to the clinicians in optimizing the diagnosis and treatment selection for the management of chronic HCV infection in resource-limited settings.